Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

Inclusion Criteria: * Type II Diabetes. * Mild-moderate diabetes retinopathy. * Diffuse clinically significant macular edema (demonstrated by angiofluoresceingraphy, associated or not to cystic changes). * Age between 50 to 75 years. * Foveal thickening greater than 300 microns tested with Optical Coherence Tomography (OCT). * Visual acuity better than 0,05. * None of the exclusion criteria. * Informed consent signed. * Data protection consent signed. Exclusion Criteria: * Bad metabolic control in recruitment stage (as criteria from Endocrinology Department of each Center) or Glicosilated Hemoglobine greater than 9%. * Uncontrolled hypertension. Greater than 150/90. * Systemic treatment with oral corticosteroids, diuretics or immunosupressors 3 months before or during the study. * Record of ocular hypertension induced by corticosteroids. * Glaucoma or ocular hypertension. * Unbalanced heart failure. * Any other pathology that could cause macular edema. * Associated ischemic maculopathy. (Parafoveal avascular area thickening greater than 1000 microns) * Patients with Clinically Significant Macular Edema with posterior hyaloid thickening or macular traction in biomicroscopy or OCT. * Patients with panretinophotocoagulation. * Patients that will probably need a panretinophotocoagulation during the study (6 to 12 months). * Record of ocular herpes infection. * Lens opacification that may interfere with clinical, photographical or OCT examinations. * Toxoplasmosis, active or no…